Russia develops cancer vaccine with 100% success rate: Details inside

MOSCOW: Russia has announced the development of Enteromix, the world’s first cancer vaccine based on mRNA technology, which has demonstrated 100% efficacy and safety in clinical trials.

The development is being hailed as a major medical breakthrough, bringing new hope to millions of cancer patients worldwide.

Clinical Trials Results & Side Effects

According to the researchers, Enteromix has already moved into early clinical use at selected oncology centers in Russia while awaiting final approval from the Ministry of Health for nationwide distribution.

During clinical testing, the vaccine showed no significant adverse effects — a notable departure from traditional cancer treatments such as chemotherapy and radiation, which often cause severe side effects including hair loss, fatigue, and organ damage.

The vaccine uses mRNA technology, the same platform that has powered several COVID-19 vaccines.

The approach enables the body’s own cells to produce proteins that mimic proteins found on cancer cells, training the immune system to identify and destroy malignant cells with precision.

Unlike traditional treatments, Enteromix selectively targets tumors, sparing healthy tissue and significantly improving patient tolerance.

Enteromix is ​​administered via a simple intramuscular injection, making it less invasive than complex cancer treatments.

It was developed by the National Medical Research Radiological Center in partnership with the Engelhardt Institute of Molecular Biology (EIMB), two leading Russian institutions specializing in oncology and molecular medicine.

Medical experts believe that Enteromix could benefit a wide range of patients, including those suffering from lung, breast, colorectal and pancreatic cancers.

It could also offer new options for people with hereditary cancer syndromes such as BRCA1/2 mutations, those with chemotherapy-resistant tumors, and even patients with compromised immune systems who typically struggle with conventional treatments.

If finally approved, Enteromix could represent a turning point in global oncology, offering patients an alternative to harsh treatments while increasing survival rates and quality of life. Oncologists are hopeful that such vaccines could pave the way for a new generation of precision medicine, shifting cancer treatment from conventional approaches to personalized, targeted medicine.